Anti-vascular endothelial growth factor for neovascular glaucoma

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Simha, Arathi ^a   Braganza, Andrew ^a   Abraham, Lekha ^a   Samuel, Prasanna ^a   Lindsley, Kristina ^b  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN A;

DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; META ANALYSIS; NEOVASCULAR GLAUCOMA; PRIORITY JOURNAL; RETINA DETACHMENT; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; VISUAL ACUITY; VITREOUS HEMORRHAGE; WORLD HEALTH ORGANIZATION; DRUG ANTAGONISM; ANTAGONISTS AND INHIBITORS; GLAUCOMA, NEOVASCULAR;

GLAUCOMA, NEOVASCULAR; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899469374     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007920.pub2     Document Type: Review

References (65)

1. Caujolle JP, Maschi C, Freton A, Pages G, Gastaud P. Treatment of neovascular glaucoma after proton therapy for uveal melanomas with ranibizumab injection: preliminary results. Ophthalmic Research 2012; Vol. 47, issue 2:57-60.
2. Costagliola C, Cipollone U, Rinaldi M, della Corte M, Semeraro F, Romano MR. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. British Journal of Clinical Pharmacology 2008;66(5):667-73.
3. Eid T, Radwan A, el-Manawy W, el-Hawary I. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Canadian Journal of Ophthalmology 2009;44(4):451-6.
4. Eid T, Radwan A, el-Menawy W, el-Hawary I. Outcome of intravitreal bevacizumab (Avastin) followed by aqueous shunting surgery for management of intractable neovascular glaucoma. American Academy of Ophthalmology. 2008:219.
5. Georgalas I, Koutsandrea C, Papaconstantinou D, Petrou P, Ladas I. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. European Journal of Ophthalmology 2010; Vol. 20, issue 1:251.
6. Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. European Journal of Ophthalmology 2009;19(3):435-41.
7. Jonas JB, Golubkina L, Libondi T, Rensch F. Intravitreal bevacizumab for neovascular glaucoma. Acta Opthalmologica 2010; Vol. 88, issue 2:e22-3.
8. Miki A, Oshima Y, Otori Y, Matsushita K, Nishida K. One-year results of intravitreal bevacizumab as an adjunct to trabeculectomy for neovascular glaucoma in eyes with previous vitrectomy. Eye 2011; Vol. 25, issue 5:658-9.
9. NCT01711879. Use of intravitreal aflibercept injection for neovascular glaucoma. clinicaltrials.gov/ct2/show/NCT01711879 (accessed 21 August 2013).
10. Sedghipour MR, Mostafaei A, Taghavi Y. Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma. Clinical Ophthalmology 2011; Vol. 5, issue 1:797-800.
11. Wittstrom E, Holmberg H, Hvarfner C, Andreasson S. Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. European Journal of Ophthalmology 2012;22(4):563-74.
12. Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. Journal of Glaucoma 2009;18(8):632-7.
13. Arcieri ES, Secches DJL, Paula JS, Barella KA, Arcieri RS, Jorge R, et al.Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed Glaucoma Valve implantation - preliminary report. ARVO. 2010:627/A471.
14. Chakrabarti M, Chakrabarti A, Stephen V, John SR. Efficacy of combining intravitreal bevacizumab monotherapy with panretinal photocoagulation in early stages of neovascular glaucoma. American Academy of Ophthalmology. 2008:182.
15. NCT01128699. Ahmed valve glaucoma implant with adjunctive subconjunctival bevacizumab in refractory glaucoma. clinicaltrials.gov/ct2/show/NCT01128699 (accessed 20 August 2013).
16. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine 1994;331(22):1480-7.
17. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Current Opinion in Ophthalmology 2007;18(6):502-8.
18. Assaad MH, Baerveldt G, Rockwood EJ. Glaucoma drainage devices: pros and cons. Current Opinion in Ophthalmology 1999;10(2):147-53.
19. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26(3):352-4.
20. Blankenship GW. A clinical comparison of central and peripheral argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1988;95(2):170-7.
21. Bloom PA, Tsai JC, Sharma K, Miller MH, Rice NS, Hitchings RA, et al."Cyclodiode". Trans-scleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma. Ophthalmology 1997;104(9):1508-19.
22. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116(9):1731-9.
23. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355(14):1432-44.
24. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, et al.Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology 2007;125(11):1460-9.
25. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
26. Delgado MF, Dickens CJ, Iwach AG, Novack GD, Nychka DS, Wong PC, et al.Long-term results of noncontact neodymium:yttrium-aluminum-garnet cyclophotocoagulation in neovascular glaucoma. Ophthalmology 2003;110(5):895-9.
27. Doft BH, Blankenship G. Retinopathy risk factor regression after laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1984;91(12):1453-7.
28. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008;28(5):696-702.
29. Feibel RM, Bigger JF. Rubeosis iridis and neovascular glaucoma. Evaluation of cyclocryotherapy. American Journal of Ophthalmology 1972;74(5):862-7.
30. Gandhi JS. Use of antivascular agents for neovascular glaucoma: benefits beyond pressure?. Clinical and Experimental Ophthalmology 2008;36(1):102-3.
31. Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR. Role of intravitreal bevacizumab in neovascular glaucoma. Journal of Ocular Pharmacology and Therapeutics 2007;23(5):487-91.
32. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU. Intracameral bevacizumab for iris rubeosis. American Journal of Ophthalmology 2006;142(1):158-60.
33. Grover S, Gupta S, Sharma R, Brar VS, Chalam KV. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. British Journal of Ophthalmology 2009; Vol. 93, issue 2:273-4.
34. Hayreh SS, Klugman MR, Podhajsky P, Servais GE, Perkins ES. Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study. Graefe's Archive for Clinical and Experimental Ophthalmology 1990;228(4):281-96.
35. Hayreh SS. Management of central retinal vein occlusion. Ophthalmologica 2003;217(3):167-88.
36. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
37. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
38. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. American Journal of Ophthalmology 2006;142(6):1054-6.
39. Katz GJ, Higginbotham EJ, Lichter PR, Skuta GL, Musch DC, Bergstrom TJ, et al.Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Ophthalmology 1995;102(9):1263-9.
40. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Advances in Therapy 2008;25(5):438-43.
41. Kiuchi Y, Nakae K, Saito Y, Ito S, Ito N. Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology 2006;244(12):1627-32.
42. Kotecha A, Spratt A, Ogunbowale L, dell'Omo R, Kulkarni A, Bunce C, Franks WA. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Archives of Ophthalmology 2011;129(2):145-50.
43. Kovacic Z, Ivanisevic M, Rogosic V, Plavec A, Karelovic D. Cyclocryocoagulation in treatment of neovascular glaucoma [Ciklokriokoagulacija u lijecenju neovaskularnoga glaukoma]. Lijecnicki Vjesnik 2004;126(9-10):240-2.
44. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al.A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. American Journal of Ophthalmology 2009;148(1):43-58.
45. Martínez-Carpio PA, Bonafonte-Márquez E, Heredia-García CD, Bonafonte-Royo S. Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review [Eficacia y seguridad de la inyección intravítrea de bevacizumab en el tratamiento del glaucoma neovascular: revisión sistemática]. Archivos de la Socidad Espanola de Oftalmologia 2008;83(10):579-88.
46. Meyer CF, Eter N, Holz FG. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial (abstract). Investigative Ophthalmology and Visual Science. 2008:E-abstract 273.
47. Minckler D, Vedula SS, Li T, Mathew M, Ayyala R, Francis B. Aqueous shunts for glaucoma. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004918.pub2]
48. NCT00406471. Rubeosis anti-VEGF (RAVE) trial for ischemic central retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT00406471 (accessed 9 November 2012).
49. Ohnishi Y, Ishibashi T, Sagawa T. Fluorescein gonioangiography in diabetic neovascularisation. Graefe's Archive for Clinical and Experimental Ophthalmology 1994;232(4):199-204.
50. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. American Journal of Ophthalmology 2006;142(1):155-8.
51. Pagenstecher M. Contribution to the teachings of hemorrhagic glaucoma [Beitrage zur Lehre vom hämorrhagischen Glaucom]. Graefe's Archive for Clinical and Experimental Ophthalmology 1871;17:98-130.
52. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
53. Rogell GD. Incremental panretinal photocoagulation. Results in treating proliferative diabetic retinopathy. Retina 1983;3(4):308-11.
54. Sone H, Okuda Y, Kawakami Y, Hanatani M, Suzuki H, Kozawa T, et al.Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated. Diabetes Care 1996;19(11):1306-7.
55. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998;105(2):232-7.
56. Tsai JC, Feuer WJ, Parrish RK 2nd, Grajewski AL. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology 1995;102(6):887-92.
57. Tsai JT, Wand M. Chapter 213: Neovascular Glaucoma. In: Alm A, Grosskreutz C editor(s). Albert and Jakobiec's Principles and Practice of Ophthalmology. 3rd Edition. Vol. 2, Canada: Saunders Elsevier, 2008:2689.
58. Vasudev D, Blair MP, Galasso J, Kapur R, Vajaranant T. Intravitreal bevacizumab for neovascular glaucoma. Journal of Ocular Pharmacology and Therapeutics 2009;25(5):453-8.
59. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, et al.Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113(6):992-1001.
60. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al.Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115(9):1571-80.
61. Wilkins M, Indar A, Wormald R. Intraoperative Mitomycin C for glaucoma surgery. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD002897.pub2]
62. Wormald R, Wilkins M, Bunce C. Postoperative 5-Fluorouracil for glaucoma surgery. Cochrane Database of Systematic Reviews 2001, Issue 3. [DOI: 10.1002/14651858.CD001132]
63. Yalvac IS, Eksioglu U, Satana B, Duman S. Long-term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma. Eye 2007;21(1):65-70.
64. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. Journal of Glaucoma 2007;16(5):437-9.
65. Simha A, Braganza A, Abraham L, Samuel P, Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007920]